Scott Morenstein

Scott Morenstein is a Managing Director and Portfolio Manager at CAM Capital, where he has led the firm’s investment strategy in both private and public life sciences companies since 2013. CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. Prior to joining CAM Capital in 2013, Mr. Morenstein was a Partner at Valence Life Sciences and before that Principal at Caxton Advantage Venture Partners, life sciences focused venture capital firms affiliated with Caxton Associates, which he joined in 2007.

Prior to joining Caxton Advantage, Mr. Morenstein was an investment banker and research analyst at Seaview Securities and Lehman Brothers from 2000-2005. Mr. Morenstein served as a director and CAM was the largest investor in Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals. He was nominated a director of Synta Pharmaceuticals to advise the company as it explored strategic alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He served as a member of Gemin X’s board of directors until its acquisition by Cephalon. He currently serves as a director of Molecular Templates (Nasdaq: MTEM), Antios Therapeutics, Primmune Therapeutics, and Velicept Therapeutics.